Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
While hematopoietic stem cell transplant (HSCT) is an effective therapy, graft versus host
disease (GVHD) is the most significant complication after HSCT. Both acute GVHD and chronic
GVHD are leading causes of non-relapse morbidity and mortality.
Acute graft versus host disease usually occurs within the first 100 days of transplant and
can involve the skin, gut, or liver. Chronic graft versus host disease usually occurs after
the first 100 days of transplant and can involve skin, eyes, mouth, joints, liver, intestines
commonly. These two diseases are different, but both happen due to the imbalance of the donor
immune system in the host.
The purpose of this research is to learn more about ruxolitinib as a treatment for both acute
and chronic GVHD. Specifically, the investigators would like to learn more about the
pharmacokinetics (PK - the process of absorption, distribution, metabolism, and elimination
from the body - meaning how the drug moves through the body) and the pharmacodynamics (PD -
the body's biological response to the drug) of ruxolitinib.